{"id":"standard-of-care-sars-cov-2-treatment","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"2-5%","effect":"Increased liver enzymes"},{"rate":"2-5%","effect":"Anemia"},{"rate":"2-5%","effect":"Thrombocytopenia"},{"rate":"2-5%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Remdesivir is a nucleotide analog that acts as a chain terminator during viral RNA synthesis, thereby preventing the virus from replicating. This mechanism of action is specific to the SARS-CoV-2 virus and is not effective against other types of viruses.","oneSentence":"Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:21.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy"}]},"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT05254990","phase":"PHASE3","title":"Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-04-27","conditions":"Infectious Pneumonia, Severe COVID-19","enrollment":414},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT06031038","phase":"NA","title":"Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU","status":"COMPLETED","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2020-09-15","conditions":"Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis","enrollment":290},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT07154888","phase":"NA","title":"Fast Track to Fertility","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-04-25","conditions":"Infertility","enrollment":160},{"nctId":"NCT04910269","phase":"PHASE3","title":"Outpatient Treatment With Anti-Coronavirus Immunoglobulin","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-06","conditions":"COVID, SARS-CoV2 Infection, Covid19","enrollment":820},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT06202521","phase":"PHASE2","title":"CX-4945 in Viral Community Acquired Pneumonia","status":"TERMINATED","sponsor":"Senhwa Biosciences, Inc.","startDate":"2024-03-20","conditions":"Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia","enrollment":45},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT06189066","phase":"NA","title":"Long COVID Ultrasound Trial","status":"COMPLETED","sponsor":"SecondWave Systems Inc.","startDate":"2024-01-03","conditions":"Long Covid","enrollment":15},{"nctId":"NCT07085611","phase":"NA","title":"Neutralizing Power of Serum Antibodies - 2","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-08-22","conditions":"COVID-19, SARS-CoV-2 Viraemia, Monkey Pox","enrollment":30},{"nctId":"NCT07280572","phase":"PHASE3","title":"RECLAIM Adaptive Platform Trial for PCC Treatments","status":"ENROLLING_BY_INVITATION","sponsor":"Janneke van de Wijgert","startDate":"2025-02-17","conditions":"Post COVID Condition","enrollment":1250},{"nctId":"NCT06992401","phase":"","title":"Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","status":"NOT_YET_RECRUITING","sponsor":"Tamara C Tamas","startDate":"2026-08-01","conditions":"Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID, Long COVID Fatigue","enrollment":50},{"nctId":"NCT07110714","phase":"NA","title":"Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","status":"RECRUITING","sponsor":"Eggensberger OHG","startDate":"2025-12-01","conditions":"Post COVID-19 Condition, Post COVID-19 Condition (PCC), Post COVID-19","enrollment":30},{"nctId":"NCT04393038","phase":"PHASE2, PHASE3","title":"ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","status":"TERMINATED","sponsor":"Abivax S.A.","startDate":"2020-07-01","conditions":"COVID-19","enrollment":509},{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT05732285","phase":"NA","title":"A Pilot Randomized Controlled Trial: CoINTEGRATE","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2023-09-01","conditions":"Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury","enrollment":15},{"nctId":"NCT05113641","phase":"NA","title":"Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)","status":"RECRUITING","sponsor":"Dylan MacKay","startDate":"2023-08-04","conditions":"Chronic Kidney Diseases, Metabolic Acidosis","enrollment":40},{"nctId":"NCT04803370","phase":"NA","title":"Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2020-07-08","conditions":"Covid19","enrollment":55},{"nctId":"NCT04482621","phase":"PHASE2","title":"Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","status":"SUSPENDED","sponsor":"Johns Hopkins University","startDate":"2020-09-14","conditions":"COVID-19","enrollment":33},{"nctId":"NCT06821113","phase":"NA","title":"Vale+Tú Salud: Corner-Based Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-07-03","conditions":"COVID-19","enrollment":150},{"nctId":"NCT06234462","phase":"PHASE2","title":"A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-06","conditions":"Long COVID, Post-Acute COVID-19 Syndrome","enrollment":""},{"nctId":"NCT04473053","phase":"PHASE1, PHASE2","title":"DEFINE - Evaluating Therapies for COVID-19","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2020-07-03","conditions":"COVID-19","enrollment":71},{"nctId":"NCT04467840","phase":"PHASE2, PHASE3","title":"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2020-08-21","conditions":"COVID-19, Lung Infection","enrollment":475},{"nctId":"NCT07090486","phase":"","title":"A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-15","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05459532","phase":"PHASE2, PHASE3","title":"A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2022-08-12","conditions":"COVID-19","enrollment":59},{"nctId":"NCT07029048","phase":"","title":"Oxidative Stress and Cognitive Dysfunction After COVID-19","status":"COMPLETED","sponsor":"Karaganda Medical University","startDate":"2021-03-01","conditions":"COVID 19, Oxydative Stress, Cognitive Impairments","enrollment":45},{"nctId":"NCT04324073","phase":"PHASE2, PHASE3","title":"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-27","conditions":"Corona Virus Infection","enrollment":239},{"nctId":"NCT04331808","phase":"PHASE2","title":"CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-30","conditions":"Corona Virus Infection","enrollment":228},{"nctId":"NCT04341584","phase":"PHASE2","title":"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-08","conditions":"Corona Virus Infection","enrollment":161},{"nctId":"NCT05022472","phase":"PHASE4","title":"Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California","status":"COMPLETED","sponsor":"Britt Skaathun","startDate":"2021-07-16","conditions":"Vaccine Refusal, Covid19","enrollment":1051},{"nctId":"NCT04347226","phase":"PHASE2","title":"Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-04-16","conditions":"Solid Tumor, Sars-CoV2, Hematological Malignancy","enrollment":43},{"nctId":"NCT04969991","phase":"PHASE2","title":"Study of Varespladib in Patients Hospitalized With Severe COVID-19","status":"TERMINATED","sponsor":"Ophirex, Inc.","startDate":"2021-06-30","conditions":"Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":18},{"nctId":"NCT04979884","phase":"PHASE3","title":"Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-03","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis","enrollment":66},{"nctId":"NCT05630482","phase":"NA","title":"Randomized Trial of Healthy Family Foundations","status":"RECRUITING","sponsor":"Penn State University","startDate":"2023-05-15","conditions":"Obesity","enrollment":825},{"nctId":"NCT06146361","phase":"NA","title":"Vale+Tú Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-11-03","conditions":"COVID-19","enrollment":359},{"nctId":"NCT04904536","phase":"PHASE3","title":"Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The George Institute","startDate":"2022-03-10","conditions":"Neurocognitive Impairment, Mild","enrollment":190},{"nctId":"NCT04852770","phase":"NA","title":"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2020-04-06","conditions":"Posttraumatic Stress Disorder, Covid19","enrollment":135},{"nctId":"NCT04937543","phase":"PHASE2","title":"Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-28","conditions":"Covid19","enrollment":50},{"nctId":"NCT06780566","phase":"NA","title":"Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in the Emergency Department Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-04-30","conditions":"Influenza, COVID-19, Acute Respiratory Infections (ARIs)","enrollment":1050},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":"COVID-19, Immunosuppression, Vaccine Response Impaired","enrollment":50},{"nctId":"NCT04884490","phase":"PHASE2, PHASE3","title":"The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-05-15","conditions":"COVID-19 Pneumonia","enrollment":94},{"nctId":"NCT04536090","phase":"PHASE2","title":"Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2022-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05445427","phase":"NA","title":"Vagal Nerve Stimulation for Post COVID Fatigue","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-12-21","conditions":"Post COVID Syndrome, Fatigue, Headache","enrollment":18},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT04900961","phase":"NA","title":"CISCO-21 Prevent and Treat Long COVID-19.","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2021-06-01","conditions":"Covid19","enrollment":233},{"nctId":"NCT04410328","phase":"PHASE3","title":"Aggrenox To Treat Acute Covid-19","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-10-21","conditions":"Covid19","enrollment":98},{"nctId":"NCT04790240","phase":"PHASE1, PHASE2","title":"Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)","status":"RECRUITING","sponsor":"All Natural Medicine Clinic, LLC","startDate":"2025-01-01","conditions":"Covid19 Virus Infection","enrollment":100},{"nctId":"NCT05269888","phase":"","title":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2022-02-16","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT05739175","phase":"NA","title":"The Effect of the Mobile Application-based Support Program on the Outcomes of Breast Cancer Patients in the Pandemic","status":"COMPLETED","sponsor":"Ankara University","startDate":"2022-07-15","conditions":"Breast Cancer, Nursing","enrollment":100},{"nctId":"NCT04359654","phase":"PHASE2","title":"Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-06-16","conditions":"COVID-19 (Coronavirus Disease 2019), Hypoxia","enrollment":41},{"nctId":"NCT04345523","phase":"PHASE2","title":"Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Cristina Avendaño Solá","startDate":"2020-04-03","conditions":"COVID-19","enrollment":350},{"nctId":"NCT06680180","phase":"","title":"Fibrinolysis Resistance in Infection and Trauma","status":"RECRUITING","sponsor":"Anders Aneman","startDate":"2024-06-01","conditions":"Sepsis and Septic Shock, Trauma","enrollment":150},{"nctId":"NCT04558476","phase":"PHASE2","title":"Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation","status":"COMPLETED","sponsor":"University of Liege","startDate":"2020-09-11","conditions":"Covid19, Mechanical Ventilation Complication, Corona Virus Infection","enrollment":475},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05305651","phase":"PHASE4","title":"Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-07-01","conditions":"COVID-19","enrollment":217},{"nctId":"NCT06610643","phase":"NA","title":"Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-21","conditions":"COVID-19, SARS-CoV-2, Immunocompromised","enrollment":40},{"nctId":"NCT05157243","phase":"PHASE3","title":"Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness","status":"WITHDRAWN","sponsor":"Romark Laboratories L.C.","startDate":"2024-08","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT05463380","phase":"","title":"Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project","status":"RECRUITING","sponsor":"Euresist Network GEIE","startDate":"2022-02-23","conditions":"COVID-19","enrollment":22000},{"nctId":"NCT04390152","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19","status":"TERMINATED","sponsor":"BioXcellerator","startDate":"2020-01-13","conditions":"Acute Respiratory Distress Syndrome","enrollment":6},{"nctId":"NCT05648799","phase":"NA","title":"Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)","status":"COMPLETED","sponsor":"Geropharm","startDate":"2022-03-17","conditions":"Pharmacokinetics, Safety Issues, Efficacy","enrollment":246},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04390594","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","status":"TERMINATED","sponsor":"Institut Pasteur de Dakar","startDate":"2020-08-13","conditions":"COVID-19","enrollment":59},{"nctId":"NCT04878055","phase":"PHASE3","title":"Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2021-02-14","conditions":"Pneumonia, Viral","enrollment":287},{"nctId":"NCT04345991","phase":"PHASE2","title":"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-15","conditions":"Covid19","enrollment":120},{"nctId":"NCT05497089","phase":"PHASE2","title":"Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome","status":"COMPLETED","sponsor":"GeNeuro SA","startDate":"2022-08-29","conditions":"Post-COVID-19 Syndrome","enrollment":203},{"nctId":"NCT04541680","phase":"PHASE3","title":"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-29","conditions":"SARS-Cov-2 Induced Pulmonary Fibrosis","enrollment":250},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT05254301","phase":"NA","title":"Nutrition and LOComotoric Rehabilitation in Long COVID-19","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-04-24","conditions":"COVID-19","enrollment":65},{"nctId":"NCT06237660","phase":"","title":"Longitudinal Preschool Wheeze Biomarker Study","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-02-01","conditions":"Wheezing","enrollment":150},{"nctId":"NCT04666025","phase":"","title":"SARS-CoV-2 Donor-Recipient Immunity Transfer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-09-23","conditions":"Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT05848427","phase":"","title":"The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19","status":"RECRUITING","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT05601180","phase":"NA","title":"Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2022-10-27","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, Long COVID","enrollment":402},{"nctId":"NCT05760092","phase":"PHASE2","title":"The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2023-03-01","conditions":"Xerostomia, COVID-19, Long COVID","enrollment":10},{"nctId":"NCT04646044","phase":"PHASE1","title":"A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2020-11-13","conditions":"Covid-19, Coronavirus Disease 2019","enrollment":30},{"nctId":"NCT04952389","phase":"NA","title":"Acupuncture Therapy for COVID-Related Olfactory Loss","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-07","conditions":"Olfactory Dysfunction, COVID-19","enrollment":30},{"nctId":"NCT04405102","phase":"PHASE2","title":"COVID-19 Ozanimod Intervention Study","status":"TERMINATED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2020-09-16","conditions":"COVID-19","enrollment":43},{"nctId":"NCT04169217","phase":"NA","title":"POWER: PrehabilitatiOn Workshop and Mentored Exercise Programme in Patients Having Elective Aortic Aneurysm Repair","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2019-11-15","conditions":"Vascular Surgery","enrollment":45},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04536350","phase":"PHASE2","title":"Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS","status":"TERMINATED","sponsor":"Prof. Dr. Jörg Leuppi","startDate":"2021-05-18","conditions":"Covid19, Corona Virus Infection, ARDS","enrollment":83},{"nctId":"NCT04842331","phase":"PHASE2, PHASE3","title":"PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)","status":"WITHDRAWN","sponsor":"Thirty Respiratory Limited","startDate":"2021-09","conditions":"Respiratory Viral Infection, Respiratory Tract Diseases, COVID-19 Respiratory Infection","enrollment":""},{"nctId":"NCT04743401","phase":"NA","title":"Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-07-05","conditions":"COVID 19, Rehabilitation, Inpatient","enrollment":54},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04368845","phase":"NA","title":"Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study","status":"COMPLETED","sponsor":"University of Thessaly","startDate":"2020-04-01","conditions":"COVID-19, Comorbidities and Coexisting Conditions","enrollment":82},{"nctId":"NCT05783206","phase":"PHASE2, PHASE3","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2022-02-10","conditions":"COVID-19","enrollment":984},{"nctId":"NCT05069610","phase":"PHASE1, PHASE2","title":"Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2022-03-21","conditions":"COVID-19","enrollment":30},{"nctId":"NCT05077930","phase":"PHASE2","title":"Convalescent Plasma Therapy for Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Tânia Portella Costa","startDate":"2022-01-06","conditions":"COVID-19, Convalescent Plasma, SARS-CoV-2","enrollment":38},{"nctId":"NCT04894266","phase":"PHASE2, PHASE3","title":"An Open-Label Study of Apabetalone in Covid Infection","status":"TERMINATED","sponsor":"Resverlogix Corp","startDate":"2022-01-14","conditions":"COVID-19 Infection","enrollment":1},{"nctId":"NCT04843774","phase":"","title":"Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-04-20","conditions":"Multiple Sclerosis","enrollment":64},{"nctId":"NCT04660084","phase":"NA","title":"Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP","status":"TERMINATED","sponsor":"Haukeland University Hospital","startDate":"2020-09-25","conditions":"Pneumonia","enrollment":374},{"nctId":"NCT04896606","phase":"PHASE1, PHASE2","title":"SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease","status":"UNKNOWN","sponsor":"New York Medical College","startDate":"2021-09-20","conditions":"Covid19","enrollment":50},{"nctId":"NCT04330690","phase":"PHASE3","title":"Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-03-18","conditions":"COVID-19","enrollment":2900},{"nctId":"NCT04988282","phase":"PHASE4","title":"Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease","status":"COMPLETED","sponsor":"Turkish Thoracic Society","startDate":"2021-05-24","conditions":"Covid19, COVID-19 Pneumonia, Interstitial Lung Disease","enrollment":262},{"nctId":"NCT04652765","phase":"PHASE1","title":"Camostat With Bicalutamide for COVID-19","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-02-03","conditions":"Covid19, SARS-CoV Infection, Coronavirus Infection","enrollment":6},{"nctId":"NCT05713279","phase":"NA","title":"Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection","status":"UNKNOWN","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2023-01-19","conditions":"COVID-19","enrollment":66},{"nctId":"NCT04321993","phase":"PHASE2","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","status":"UNKNOWN","sponsor":"Lisa Barrett","startDate":"2020-04-17","conditions":"COVID-19","enrollment":363}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard-of-care SARS-CoV-2 treatment","genericName":"Standard-of-care SARS-CoV-2 treatment","companyName":"Chita State Regional Clinical Hospital Number 1","companyId":"chita-state-regional-clinical-hospital-number-1","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus. Used for Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}